# Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

> **NCT01529840** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 24 (actual)

## Conditions studied

- Genetic Disorder
- Noonan Syndrome

## Interventions

- **DRUG:** somatropin
- **DRUG:** somatropin

## Key facts

- **NCT ID:** NCT01529840
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1990-06
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01529840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01529840, "Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01529840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*